The efficacy and safety of prostatic urethral lift as a minimally invasive therapeutic modality to treat lower urinary tract symptoms while maintaining sexual function in patients with benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
https://doi.org/10.4081/aiua.2024.12066
Accepted: December 5, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background: Benign prostatic hyperplasia (BPH) is prevalent among elderly men, necessitating focused attention. The Prostatic Urethral Lift (PUL) procedure, a minimally invasive intervention, has emerged as a promising option for BPH management. It has shown remarkable results in ameliorating lower urinary tract symptoms (LUTS), enhancing quality of life, and preserving sexual function. This study aims to evaluate the effectiveness and safety of PUL in BPH patients.
Methods: Key databases (MEDLINE, Cochrane CENTRAL, ScienceDirect, EBSCO, Google Scholar) were systematically searched using pertinent terms related to PUL and BPH. Following the PRISMA checklist, we considered only randomized controlled trials (RCTs) from 2013 to 2023. The assessment focused on LUTS, quality of life, sexual function, and adverse events within three months. Follow-up post-treatment mean values compared with controls (Sham) and the improvement from baseline to post-treatment follow-up duration were considered. Statistical analysis and risk of bias evaluation were conducted using Review Manager 5.4.1, presenting results as difference of mean values (MD) and risk ratios (RR).
Results: A meta-analysis with a Random Effects Model of 7 RCTs involving 378 confirmed BPH patients demonstrated significant improvements in the PUL arm including International Prostate Symptom Score (IPSS) (MD 5.51, p<0.0001), maximum urinary flow rate (Qmax) (MD 2.13, p=0.0001), BPH Impact Index (BPHII) (MD 2.14, p=0.0001), and IPSS-QoL (MD 1.50, p<0.0001), without significant increase of adverse events (RR 1.51; p=0.50). Positive outcomes were observed in sexual function variables and post-void residual measurements when post-treatment values were compared to baseline.
Conclusions: PUL holds advantages over control interventions, providing encouraging prospects for BPH management. This study underscores the need for further exploration of PUL's efficacy and safety in BPH patients.
Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019;65:458-464. DOI: https://doi.org/10.1159/000496289
Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43:289-97. DOI: https://doi.org/10.1016/j.ucl.2016.04.001
Lokeshwar SD, Harper BT, Webb E, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8:529-39. DOI: https://doi.org/10.21037/tau.2019.10.01
De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017 3:352-63. DOI: https://doi.org/10.1016/j.euf.2017.11.004
Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of PUL versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68:643-52. DOI: https://doi.org/10.1016/j.eururo.2015.04.024
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. DOI: https://doi.org/10.1371/journal.pmed.1000097
Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Heal Serv Res Policy. 2002;7:51-61. DOI: https://doi.org/10.1258/1355819021927674
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Available from: https://handbook-5-1.cochrane.org/
Roehrborn CG, Rukstalis DB, Barkin J, et al. Three-year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015;22:7772-82.
Bozkurt A, Karabakan M, Keskin E, et al. Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urol Int. 2016;96:202-6. DOI: https://doi.org/10.1159/000441850
Perera M, Roberts MJ, Doi SAR, Bolton D. Prostatic Urethral Lift improves urinary symptoms and flow while preserving sexual function for men with benign. Eur Urol. 2015;67:704-13. DOI: https://doi.org/10.1016/j.eururo.2014.10.031
Cantwell AL, Bogache WK, Richardson SF, et al. Prostatic Urethral Lift for the treatment of LUTS. BJU Int. 2014;113:615-22. DOI: https://doi.org/10.1111/bju.12540
Eure G, Rukstalis D, Roehrborn C. Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings. J Endourol. 2023;37:50-9. DOI: https://doi.org/10.1089/end.2022.0324
McVary KT, Gange SN, Shore ND, et al. Prostatic Urethral Lift for BPH Preserves Sexual Function. J Sex Med. 2014;11:279-287. DOI: https://doi.org/10.1111/jsm.12333
Rukstalis D, Rashid P, Bogache WK, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded Sham. BJU Int. 2016;118:14-22. DOI: https://doi.org/10.1111/bju.13666
Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190:2161-7. DOI: https://doi.org/10.1016/j.juro.2013.05.116
Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802-13.
Dawu AE, Tosepu R, Effendy DS. Benign Prostate Hyperplasia (BPH) in Inpatient Rooms at Aliyah II General Hospital Kendari, Southeast Sulawesi, Indonesia. KnE Life Sci. 2022;78-81. DOI: https://doi.org/10.18502/kls.v0i0.11780
Chughtai B, Forde IC, Thomas DDM, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031. DOI: https://doi.org/10.1038/nrdp.2016.31
Wang YB, Yang L, Deng YQ, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med. 2022;20:495. DOI: https://doi.org/10.1186/s12967-022-03722-y
Engström G, Henningsohn L, Engström MLW, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol. 2006;40:485-94. DOI: https://doi.org/10.1080/00365590600830862
Burke N, Whelan JP, Goeree L, et al. Systematic review and metaanalysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology. 2010;75:1015-22. DOI: https://doi.org/10.1016/j.urology.2009.08.015
Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97:e13360. DOI: https://doi.org/10.1097/MD.0000000000013360
Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol. 2014;21:7094-101.
Pessoa R, Kim FJ. Urodynamics and voiding dysfunction. In: AH Harken, EE Moore, editors. Abernathy’s surgical secrets, 7th ed. Amsterdam, Elsevier; 2018. pp. 452-54. DOI: https://doi.org/10.1016/B978-0-323-47873-1.00103-0
Johnson TV, Abbasi A, Ehrlich SS, et al. IPSS quality of life question: a possible indicator of depression among patients with lower urinary tract symptoms. Can J Urol. 2012;19:6100-4.
Favilla V, Cimino S, Salamone C, et al. Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): a 12 months follow-up. J Endocrinol Invest 2013;36:1094-8. DOI: https://doi.org/10.1007/BF03346761
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
